Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Taking gastro-surveillance into the 21st century

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Molecular epidemiology of human adenovirus infections in Denmark, 2011-2016

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. BAYESIAN ANALYSIS OF BASELINE RISK OF CIN2 AND ≥CIN3 BY HPV GENOTYPE IN A EUROPEAN REFERRAL COHORT

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Intra- and inter-laboratory agreement of the FAM19A4/mir124-2 methylation test: Results from an international study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Inverted papilloma of the conjunctiva

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Background: The VALidation of HPV GENoyping Tests (VALGENT) framework is designed for comparison and clinical validation of HPV assays. Objectives: To evaluate the accuracy of the HPV-Risk assay within VALGENT-4, relative to clinically validated comparator HPV tests. Study design: The VALGENT-4 panel comprises consecutive SurePath cervical samples from routine screening (n=998), of which 51 had abnormal cytology and 13 women had cervical intraepithelial neoplasia (CIN) grade 2 or worse (CIN2+), enriched with SurePath cervical samples from 297 women with abnormal cytology and 109 CIN2+. HPV-Risk assay was performed on DNA extracted panel samples (n=1,295), blinded to clinical data, cytology results, and results from other HPV assays evaluated in VALGENT-4. All assay results were reported to the central VALGENT coordination institute for data and statistical analysis. HPV prevalence was analysed and accuracy for detection of CIN grade 3 or worse (CIN3+) and CIN2+ were assessed relative to GP5+/6+-PCR-EIA and GP5+/6+-PCR-EIA-LMNX. Results: The sensitivity of the HPV-Risk assay for detection of CIN3+ and CIN2+ was similar to that of GP5+/6+-PCR-EIA (relative sensitivity for CIN3+1.01; 95%CI: 0.97-1.06; p McN=1.000, and for CIN2+1.01; 95%CI: 0.96-1.06; p McN=1.000) at significantly higher specificity (relative specificity 1.04; 95%CI: 1.02-1.06; p McN<0.001). The accuracy of the HPV-Risk assay for CIN3+ and CIN2+ was non-inferior compared to GP5+/6+-PCR- EIA and GP5+/6+-PCR-EIA-LMNX, with all p-values ≤0.002. HPV16/18 genotype agreement between HPV-Risk assay and GP5+/6+-PCR-LMNX was high. Conclusions: The HPV-Risk assay demonstrated non-inferiority to clinically validated comparator assays on cervical samples in SurePath medium using the VALGENT-4 panel, and is therefore suitable for cervical cancer screening.

Original languageEnglish
Article number104201
JournalJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology
Volume121
ISSN1386-6532
DOIs
Publication statusPublished - Dec 2019

    Research areas

  • Cervical cancer screening, Clinical validation, HPV-risk assay, Human papillomavirus, Liquid medium, Test accuracy

ID: 58181141